Completed PHASE2 INTERVENTIONAL 1-arm NCT00210470

A Phase 2 Clinical Trial of the Safety and Effects of IRX-2 in Treating Patients With Operable Head and Neck Cancer

A Phase 2, Open-label Trial of the Safety and Biological Effect of Subcutaneous IRX-2 (With Cyclophosphamide, Indomethacin, and Zinc) in Patients With Resectable Cancer of the Head and Neck

Sponsor: Brooklyn ImmunoTherapeutics, LLC

Conditions Squamous Cell Carcinoma of the Head and Neck

Interventions Cyclophosphamide IRX-2 Indomethacin Omeprazole Zinc

Updated 9 times since 2017 Last updated: Dec 10, 2020 Started: Jul 31, 2005 Primary completion: Dec 31, 2010 Completion: Mar 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00210470, this PHASE2 trial focuses on Squamous Cell Carcinoma of the Head and Neck and remains completed. Sponsored by Brooklyn ImmunoTherapeutics, LLC, it has been updated 9 times since 2005, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2023 — Jul 2024 [monthly]

Completed PHASE2
Dec 2022 — Jan 2023 [monthly]

Completed PHASE2
Jan 2021 — Dec 2022 [monthly]

Completed PHASE2

▶ Show 4 earlier versions

Jan 2019 — Jan 2021 [monthly]

Completed PHASE2
Jun 2018 — Jan 2019 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Jul 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Brooklyn ImmunoTherapeutics, LLC

Data source: Brooklyn ImmunoTherapeutics, LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.